BDSX · Biodesix Inc · Webcasts, Transcripts & Audio
$22.75
+0.80 (+3.64%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$231.60M
Shares
10.55M
Volume · Oct 28
45.6K
Avg daily vol (3M)
102.43K
Biodesix Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Biodesix Inc (BDSX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
Biodesix Inc (BDSX) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-08-12
Biodesix Inc (BDSX) August 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Biodesix Inc (BDSX) Q2 2026 Earnings Call Transcript
Confident tone
Diagnostic test volume and revenue growth
Clinical evidence and publications
Primary care market expansion
Revenue
$26.86M
▲ 34.2% YoY Diluted EPS
$-0.71
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Biodesix Inc (BDSX) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-04
Biodesix Inc (BDSX) Q1 2026 Earnings Call Transcript
Confident tone
Lung Diagnostic Testing Growth
Profitability and Operating Leverage
Development Services / Biopharma
Revenue
$25.55M
▲ 42.3% YoY Diluted EPS
$-0.81
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Biodesix Inc (BDSX) Q4 2025 Earnings Call
Confident tone
Lung Diagnostics Growth
HEDIS / Lung Cancer Screening Guidelines
Profitability Milestones
Revenue
$28.75M*
▲ 40.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Biodesix Inc (BDSX) Q3 2025 Earnings Call Transcript
Confident tone
Lung diagnostics / Nodify testing
Sales force productivity and expansion
Revenue and margin growth
Revenue
$21.77M
▲ 19.9% YoY Diluted EPS
$-1.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Biodesix Inc (BDSX) Q2 2025 Earnings Call Transcript
Positive tone
Lung nodule diagnostic commercial expansion
Primary care sales strategy
Development Services / biopharma
Revenue
$20.02M
▲ 11.7% YoY Diluted EPS
$-1.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Biodesix Inc (BDSX) Q1 2025 Earnings Call Transcript
Positive tone
Primary Care Commercial Expansion
Sales Team Reconfiguration
Lung Diagnostics Growth (Nodify)
Revenue
$17.96M
▲ 21.2% YoY Diluted EPS
$-1.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Biodesix Inc (BDSX) Q4 2024 Earnings Call Transcript
Positive tone
Lung disease market opportunity
Clinical studies and evidence generation
Diagnostic development services / biopharma
Revenue
$20.43M*
▲ 39.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-01
Biodesix Inc (BDSX) Q3 2024 Earnings Call Transcript
Positive tone
Sales team expansion and productivity
Lung diagnostic test growth and adoption
Hurricane impact on Q3 operations
Revenue
$18.15M
▲ 34.5% YoY Diluted EPS
$-1.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Biodesix Inc (BDSX) Q2 2024 Earnings Call Transcript
Confident tone
Lung diagnostic test growth and volume
Revenue guidance raise and financial performance
Operational efficiency and facilities
Revenue
$17.93M
▲ 51% YoY Diluted EPS
$-1.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Biodesix Inc (BDSX) Q1 2024 Earnings Call Transcript
Confident tone
Lung Diagnostic test volume growth
Gross margin expansion
Path to profitability / adjusted EBITDA
Revenue
$14.82M
▲ 63.6% YoY Diluted EPS
$-2.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-01
Biodesix Inc (BDSX) Q4 2023 Earnings Call Transcript
Confident tone
Lung diagnostic test volume growth
Biopharmaceutical services
Sales force expansion
Revenue
$14.67M*
▲ 52.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Biodesix Inc (BDSX) Q3 2023 Earnings Call Transcript
Revenue
$13.49M
▲ 21.5% YoY Diluted EPS
$-2.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Biodesix Inc (BDSX) Q2 2023 Earnings Call Transcript
Revenue
$11.87M
▲ 8.4% YoY Diluted EPS
$-3.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Biodesix Inc (BDSX) Q1 2023 Earnings Call Transcript
Revenue
$9.06M
▲ 38.3% YoY Diluted EPS
$-4.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-06
Biodesix Inc (BDSX) Q4 2022 Earnings Call Transcript
Revenue
$9.61M*
▲ 33% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-11
Biodesix Inc (BDSX) Q3 2022 Earnings Call Transcript
Revenue
$11.11M
▲ 70.1% YoY Diluted EPS
$-6.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Biodesix Inc (BDSX) Q2 2022 Earnings Call Transcript
Revenue
$10.95M
▼ 7.9% YoY Diluted EPS
$-8.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Biodesix Inc (BDSX) Q1 2022 Earnings Call Transcript
Revenue
$6.55M
▼ 77.3% YoY Diluted EPS
$-10.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-14
Biodesix Inc (BDSX) Q4 2021 Earnings Call Transcript
Revenue
$7.22M*
▼ 73.3% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Biodesix Inc (BDSX) Q3 2021 Earnings Call Transcript
Revenue
$6.53M
▼ 29% YoY Diluted EPS
$-8.20
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Biodesix Inc (BDSX) Q2 2021 Earnings Call Transcript
Revenue
$11.88M
▲ 180.4% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Biodesix Inc (BDSX) Q1 2021 Earnings Call Transcript
Revenue
$28.87M
▲ 466.4% YoY
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Showing 1–25 of 25 webcasts